N-sulfonyl-4-methyleneamino-3-hydroxy-2-pyridones
Compounds of Formula (I): are effective in the treatment of a microbial infection.
1 . A compound of formula (I):
wherein:
a. R 1 is aryl, optionally substituted with one or more hydrogen, halo, cyano, hydroxy, carboxy, keto, thioketo, amino, acylamino, acyl, amido, phenyl, aryloxy, alkyl, alkenyl, alkynyl, heteroalkyl, haloalkyl, alkoxy, aryl, cycloalkyl, spirocycloalkyl or combinations thereof;
b. each R 2 is independently chosen from hydrogen, halo, cyano, hydroxy, carboxy, keto, thioketo, amino, acylamino, acyl, amido, phenyl, aryloxy, alkyl, alkenyl, alkynyl, heteroalkyl, haloalkyl, alkoxy, aryl, and cycloalkyl;
c. R 3 and R 4 , together with the nitrogen atom to which they are bonded, join to form heterocycloalkyl moieties, optionally substituted with one or more hydrogen, halo, cyano, hydroxy, carboxy, keto, thioketo, amino, acylamino, acyl, amido, alkyl, alkenyl, alkynyl, heteroalkyl, haloalkyl, alkoxy, substituted or unsubstituted aryl, substituted or unsubstituted heteroaryl, heterocycloalkyl, spirocycloalkyl, and combinations thereof; and
d. R 5 and R 6 are each independently chosen from hydrogen, halo, cyano, hydroxy, carboxy, keto, thioketo, amino, acylamino, acyl, amido, phenyl, aryloxy, alkyl, alkenyl, alkynyl, heteroalkyl, haloalkyl, alkoxy, aryl, and cycloalkyl; or
optical isomers, diastereomers and enantiomers of the formula above, or a pharmaceutically-acceptable salt thereof.
2 . The compound of claim 1 , wherein R 1 is substituted or unsubstituted phenyl.
3 . The compound of claim 2 , wherein the phenyl group of R 1 is substituted with an alkyl.
4 . The compound of claim 1 , wherein R 1 is aryl substituted with a heteroalkyl.
5 . The compound of claim 1 , wherein R 1 is aryl substituted with an aryl.
6 . The compound of claim 1 , wherein R 1 , R 2 , R 5 , and R 6 , are hydrogen.
7 . The compound of claim 1 , wherein R 1 is phenyl, substituted with methyl.
8 . The compound of claim 1 , wherein R 2 is hydrogen.
9 . The compound of claim 1 , wherein R 3 and R 4 join to form a heteroaryl.
10 . The compound of claim 1 , wherein R 3 and R 4 join to form a heterocycloalkyl.
11 . The compound of claim 9 , wherein the heteroaryl formed by joining of R 3 and R 4 is further substituted with a heteroaryl.
12 . The compound of claim 9 , wherein the heteroaryl formed by joining of R 3 and R 4 is further substituted with a heterocycloalkyl.
13 . The compound of claim 10 , wherein the heterocycloalkyl formed by joining of R 3 and R 4 is further substituted with a heteroaryl.
14 . The compound of claim 10 , wherein the heterocycloalkyl formed by joining of R 3 and R 4 is further substituted with a heterocycloalkyl.
15 . The compound of claim 1 , wherein R 5 and R 6 are hydrogen.
16 . The compound of claim 1 , selected from the group consisting of:
3-Hydroxy-4-pyrrolidin-1-ylmethyl-1-(toluene-4-sulfonyl)-1H-pyridin-2-one;
3-Hydroxy-4-thiazolidin-3-ylmethyl-1-(toluene-4-sulfonyl)-1H-pyridin-2-one;
4-Azocan-1ylmethyl-3-hydroxy-1-(toluene-4-sulfonyl)-1H-pyridin-2-one; and
4-[1,4′]Bipiperidinyl-1′-ylmethyl-3-hydroxy-1-(toluene-4-sulfonyl)-1H-pyridin-2-one.
17 . A method of treating a microbial infection comprising administering a safe and effective of amount of a compound according to claim 1 , in a subject in need thereof.
18 . A method of treating a microbial infection comprising administering a safe and effective of amount of a compound according to claim 16 , in a subject in need thereof.
19 . A pharmaceutical composition comprising:
a. a safe and effective of amount of a compound according to claim 1;
b. a pharmaceutically-acceptable excipient.
20 . A pharmaceutical composition comprising:
a. a safe and effective of amount of a compound according to claim 16;
b. a pharmaceutically-acceptable excipient.